Figure 4From: Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion Forest plot of indirect relative risk ±95% CI at Month 6 for patients with BRVO. In the upper point estimates, values <1 would indicate greater chance of improving with ranibizumab; in the bottom point estimates, values >1 would indicate greater risk of worsening with dexamethasone.Back to article page